Cardiff Oncology, Inc. (CRDF) Market Cap
Cardiff Oncology, Inc. has a market capitalization of $118.3M.
Financials based on reported quarter end 2025-12-31
Price: $1.73
▲ 0.08 (4.85%)
Market Cap: 118.27M
NASDAQ · time unavailable
CEO: Mani Mohindru
Sector: Healthcare
Industry: Biotechnology
IPO Date: 2004-07-27
Website: https://www.cardiffoncology.com
Cardiff Oncology, Inc. (CRDF) - Company Information
Market Cap: 118.27M · Sector: Healthcare
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Analyst Sentiment
Based on 12 ratings
Consensus Price Target
No data available
Price & Moving Averages
Related Companies in Healthcare
DEFINITIVE HEALTHCARE CORP CLASS A (DH)
Healthcare
$0.12B
Mkt Cap
AVITA MEDICAL INC (RCEL)
Healthcare
$0.12B
Mkt Cap
AARDVARK THERAPEUTICS INC (AARD)
Healthcare
$0.12B
Mkt Cap
TREACE MEDICAL CONCEPTS INC (TMCI)
Healthcare
$0.12B
Mkt Cap
JOURNEY MEDICAL CORP (DERM)
Healthcare
$0.12B
Mkt Cap
JOINT CORP (JYNT)
Healthcare
$0.12B
Mkt Cap
Fundamentals Overview
📊 AI Financial Analysis
Powered by StockMarketInfo"CRDF (latest quarter 2025-12-31) reported Revenue of $0.243M and Net Income of -$7.22M (EPS -0.11). Revenue surged QoQ from $0.120M (2025-09-30) to $0.243M (+102.5%), while losses improved QoQ as Net Income moved from -$11.26M to -$7.22M (losses narrowed by ~35.9%). Over the full 4-quarter period, revenue has generally trended up (from $0.109M in 2025-03-31 to $0.243M in 2025-12-31), but profitability remains deeply negative. Because there is no 2024-12-31 (same quarter last year) data provided, YoY growth rates cannot be calculated from the supplied history. Cash flow quality is weak: operating cash flow and free cash flow have been consistently negative (FCF -$12.79M in 2025-03-31, improving to -$5.97M in 2025-12-31). This indicates ongoing burn, even though the burn rate has eased recently. Balance sheet resilience looks mixed. Total assets declined QoQ (from $84.81M to $61.88M), and equity fell sharply (from $70.88M to $45.39M), suggesting funding pressure despite net cash positioning (netDebt remains negative). Total shareholder return is poor: the stock is down -35.94% over 1Y with no dividend support and no buyback data provided."
Revenue Growth
QoQ revenue rose from $0.120M to $0.243M (+102.5%). Over 4 quarters, revenue increased from $0.109M (2025-03-31) to $0.243M (2025-12-31). YoY growth rates cannot be computed from the provided dataset (no 2024 same-quarter values).
Profitability
Net losses persist. Losses narrowed QoQ (-$11.26M to -$7.22M; improvement ~35.9%), but net margin is still extremely negative. EPS remained negative across all quarters (from -0.17/-0.21 range to -0.11 latest), indicating some progress but no profitability.
Cash Flow Quality
FCF is consistently negative (e.g., -$12.79M in 2025-03-31 improving to -$5.97M in 2025-12-31). No dividends paid and no buyback information provided; cash burn remains a key risk.
Leverage & Balance Sheet
Net debt is negative (net cash) across quarters, which helps near-term flexibility. However, total assets fell QoQ ($84.81M to $61.88M) and equity dropped materially ($70.88M to $45.39M), indicating reduced cushion.
Shareholder Returns
1Y price change is -35.94%. No dividend yield (0) and no buyback data provided, so total shareholder return is driven by negative price momentum.
Analyst Sentiment & Valuation
No price target data is provided. With negative earnings and weak cash generation, valuation support is limited (P/E is negative across periods due to losses).
Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.
So what: Management is confident the 30 mg dose is driving a stronger efficacy signal in CRDF-004 (64% ORR vs 33% control; deepest regressions exclusively in the 30 mg arm) and claims ongoing tolerability (>380 patients dosed). Operationally, the trial is now closed to new screening and should finish enrollment in the next few weeks, supporting a more “mature and substantive” first-half 2025 update. However, the analyst Q&A pressure centered on registrational-readiness: when PFS will become evaluable and how dose selection will be justified to FDA. Management repeatedly avoided committing to PFS timing for the first half, stating it is likely too early, and framed dose selection and registrational path (trial 005, accelerated/full approval assumptions) as dependent on FDA discussions. Net: the efficacy headline is strong, but key endpoint maturation and regulatory specifics remain delayed/uncertain.
Growth Catalysts
- CRDF-004 initial efficacy signal in first-line RAS-mutated mCRC: 30 mg onvansertib ORR 64% vs 33% control (first 30 patients; data cutoff Nov 26, 2024)
- Dose-response observed: five deepest tumor regressions all occurred in patients receiving the 30 mg dose
- Safety differentiator: onvansertib well tolerated; >380 patients dosed across trials
- Upcoming clinical readout planned for first half of 2025 (more mature update vs 30-patient data cut)
Business Development
- Pfizer BREAKWATER trial outcome (encorafenib in first-line mCRC, BRAF-mutant) used by management to validate their FDA registrational approach (accelerated approval on ORR subset; later full approval with PFS)
Financial Highlights
- Cash & short-term investments at Dec 31, 2024: $91.7M (includes net proceeds from $40M capital raise completed in December 2024)
- Q4 2024 cash used in operating activities: $10.3M (in line with typical quarterly cash burn)
- Cash runway: management expects current resources into Q1 2027
- No EPS/Revenue figures or guidance provided in the transcript
Capital Funding
- Completed $40M capital raise in December 2024 (new and existing healthcare dedicated institutional investors)
- Filed shelf registration statement on Form S-3 (replaces expiring shelf); explicitly stated no share issuance involved with this filing
Strategy & Ops
- CRDF-004 enrollment operational change: closed trial to new patients entering screening (this week); expects complete enrollment in the next few weeks
- Enrollment status referenced: 60 patients dosed by December reporting time when 30-patient update was released (at least one post-baseline scan); target is 90 evaluable patients planned
Market Outlook
- Additional CRDF-004 clinical data update planned for first half of 2025 (management could not confirm PFS maturity timing within first half)
- FDA interactions cadence: management goal is to get in front of FDA ASAP; discussions planned to cover (1) dose selection (30 vs 20) and (2) finalizing trial design for registrational trial 005
- Dose selection decision timing implied to occur after FDA meeting(s) providing clarity on proceeding to registrational 005; exact date not provided
Risks & Headwinds
- PFS maturity risk/uncertainty: management indicated it is likely too early to expect PFS within the first half 2025 update, pushing key endpoint visibility beyond that window
- Registrational endpoint risk: ability to proceed with full approval assumptions depends on FDA alignment on trial design and accelerated/full approval specifics (management emphasized FDA meeting as gating factor)
- Clinical execution risk: enrollment closure to new screening suggests remaining recruitment timing constraints; however management expects complete enrollment in next few weeks
Sentiment: MIXED
Note: This summary was synthesized by AI from the CRDF Q4 2024 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.